Cardiometabolic Outcomes of Novel Therapy Tirzepatide: A Systematic Review

Authors

Osadebamwen Osaghae, Department of Medicine, Division of Internal Medicine, Reading Hospital - Tower Health, West Reading, PAFollow
Gbolahan Olatunji
Emmanuel Kokori
Nicholas Aderinto

Document Type

Abstract

Publication Date

9-1-2025

Abstract

Description: This systematic review evaluates the efficacy and safety of tirzepatide in improving cardiometabolic outcomes, beyond its glycemic and weight loss effects, in patients with type 2 diabetes and obesity. Objectives: To evaluate the role of tirzepatide in managing cardiometabolic complications associated with type 2 diabetes and obesity. Methods: A systematic review of randomized controlled trials focused on the impact of tirzepatide on lipid profiles, blood pressure, and liver health. Results: Tirzepatide showed significant reductions in hemoglobin A1C, weight loss, and improvements in blood pressure, lipid profiles, and liver health. The most common adverse events were mild gastrointestinal symptoms. Conclusion: Tirzepatide is an effective treatment for managing both glycemic control and cardiometabolic risk factors, supporting its broader role in managing type 2 diabetes and obesity.

Publication Title

Endocrinology Practice

Volume

31

Issue

9 Supplement

First Page

S199

Last Page

S199

Comments

AACE Annual Meeting 2025 held 2025-05-15 to 2025-05-17 in Orlando, FL, USA.

Recommended Citation

Osaghae, O., Olatunji, G., Kokori, E., & Aderinto, N. (2025). Cardiometabolic Outcomes of Novel Therapy Tirzepatide: A Systematic Review. Endocrinology Practice, 31 (9 Supplement), S199-S199. https://doi.org/https://doi.org/10.1016/j.eprac.2025.05.564